SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending as the community reacts to news of a government directive to purchase $200 billion in mortgage bonds, aiming to significantly lower rates. This development is sparking widespread bullish sentiment, with many anticipating a revitalized housing market, increased transaction volume, and potential for a substantial short squeeze on the stock.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies (RKT) is trending following news of former President Trump's plans to stimulate the housing market, including instructing representatives to buy $200 billion in mortgage bonds and potentially banning institutional home purchases. This has ignited community discussion around an impending refinance boom and increased housing affordability, positioning RKT's integrated mortgage and real estate platform for a significant re-rating and potential new highs. Investors are actively debating the magnitude of this positive catalyst on RKT's business model.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive is experiencing a surge in attention following its announcement as an authorized Starlink Aviation dealer, which allows the company to install high-speed internet on its private jet fleet and for third-party clients. This development is fueling widespread discussion and speculative trading activity, with the community weighing its potential for new revenue streams against market concerns regarding recent stock offerings.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is trending after releasing its 2025 update and 2026 corporate outlook, highlighting triple-digit growth for its Nociscan AI back pain platform and a strong financial position with no debt. The community is actively discussing the stock's low float and substantial cash per share, leading to speculation about a significant short squeeze reminiscent of other recent low-float runners. However, some investors remain cautious, citing the company's history of reverse splits and potential dilution concerns.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae (FNMA) is trending due to recent political statements outlining a directive for the entity to utilize its substantial cash reserves, including $200 billion, to purchase mortgage bonds aimed at lowering interest rates. This move is widely discussed within the community as a significant progression towards resolving long-standing issues and potentially paving the way for its release from conservatorship and eventual public offering. Investors are actively debating the implications of this strategy for the housing market and the entity's future, with many anticipating a major shift.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following disappointing preliminary Q4 results and a significantly lowered DefenCath revenue guidance for 2026 and 2027, primarily due to the anticipated expiration of TDAPA funding, triggering a sharp sell-off and strong community frustration with management. Despite the immediate negative reaction, many bulls see the dip as an overreaction and a buying opportunity, emphasizing that the guidance is conservative and excludes potential upsides from new customers, upcoming legislation like the Kidney Care Access Protection Act, and growth from the broader Melinta Therapeutics portfolio.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is a major focus as small-cap stocks are demonstrating significant relative strength, breaking out to new all-time highs and sharply outperforming larger indices. The community is actively discussing whether this powerful "risk-on" surge is sustainable, especially with market participants awaiting critical economic reports and a potential Supreme Court tariff ruling that could influence future market sentiment and liquidity.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending on confirmed reports that its subsidiary, Airobotics, has been selected as the prime contractor for Israel's significant drone hive border security project. This pivotal role, alongside broader discussions of increased defense spending and strategic partnerships, is fueling immense community optimism regarding its future in autonomous defense systems. Many investors are anticipating continued growth, driven by strong institutional interest and the potential for a "drone super-cycle."

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is a top trending stock, with investors closely watching its expanding AI server demand and strategic position in the fast-growing artificial intelligence infrastructure market. Community discussions highlight accusations of market manipulation by analysts and debates over potential margin impacts from memory costs, with many viewing the company as undervalued amidst its strong order backlog.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.</li><li>A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure debts.</li><li>New turnaround-focused leadership was appointed as part of the recovery plan.</li></ul>Kala Bio surged 22% after hours on Tuesday after the company disclosed a rescue financing agreement that temporarily stabilizes its operations and averts a pending asset seizure by its lender. The move marks the company's reversal since September, when its eye disease therapy KPI-012 failed a Phase 2 trial, triggering a roughly 90% collapse in the stock and a wave of analyst downgrades.<h2 class="st-heading-2">Emergency Financing Steps In After Default</h2>The after-hours rally followed Kala’s filing detailing a sequence of events that began on Sept. 29, when Oxford Finance issued a notice of default under the company’s loan agreement and declared all obligations immediately due.&nbsp;On Oct. 19, Oxford informed Kala it intended to foreclose on all remaining assets,&nbsp;sweep all of the company’s cash, and&nbsp;restrict the use of funds to minimal payroll expenses necessary to execute the foreclosure. The same day, Kala terminated all remaining employees except those required to support Oxford’s process.Oxford later paused the foreclosure on Nov. 3 and allowed Kala to access $125,000 of previously swept cash to negotiate a potential transaction. On Nov.9, Kala executed a convertible loan agreement with investor David Lazar for $375,000 to fund&nbsp;the preparation of its quarterly filing and support negotiations for further investment.<h2 class="st-heading-2">Lifeline Private Placement Up To $6 Million</h2>The company then entered into a securities purchase agreement on Nov. 23 under which Lazar agreed to provide up to $6 million in a two-stage private placement of Series AA and Series AAA preferred stock. The first closing occurred on Monday, delivering $1.8 million to Kala. The second closing, for an additional $4.2 million, requires shareholder approval to increase authorized common shares and permit conversion of the preferred stock. Kala will hold the shareholder meeting before March 31, 2026. The proceeds will fund current operations, liabilities, and expenses, with $1 million of the second closing earmarked for Oxford as part of the settlement arrangement.<h2 class="st-heading-2">Settlement Restructures Obligations</h2>As part of the rescue package, Kala and unit Combangio entered into a loan settlement agreement with Oxford on Nov. 23. Oxford agreed to settle all outstanding payment obligations in exchange for a $2 million cash settlement and 1.62 million shares of common stock.&nbsp;Once Kala pays the initial $1 million and issues the settlement shares, Oxford will release control of Kala’s bank accounts, reduce the outstanding loan balance by $7 million, and waive associated interest and final payments. The company also agreed to pay Oxford 10% of future equity financing proceeds, up to $1 million, with each such payment reducing loan obligations by 3x the amount contributed.Oxford’s foreclosure efforts will formally end once the full settlement payment is completed. Kala is committed to pursuing a “material strategic alternative transaction” within one year to clear the remaining settlement balance.<h2 class="st-heading-2">Leadership Changes Accompany Restructuring</h2>As part of the financing deal, David Lazar was appointed CEO and elected to the board on Nov. 21. Lazar brings a turnaround-focused background to the role. He currently leads Custodian Ventures LLC and Activist Investing LLC, firms that specialize in turnaround situations involving distressed public companies.Todd Bazemore, the prior CEO, stepped down from the role but remains on the board. Meanwhile, chief financial officer Mary Reumuth was terminated effective immediately following the first closing, and the company also announced settlement agreements for certain former executives tied to their contractual severence rights.<h2 class="st-heading-2">Fallout From Eye Drug Trial Failure</h2>The crisis began in late September when KPI-012, a treatment for persistent corneal epithelial defect, failed to meet all primary and secondary endpoints in the Phase 2b CHASE trial. The miss contradicted the positive signals seen in the earlier Phase 1b trial and led management to terminate development of KPI-012 and its broader mesenchymal stem cell secretome platform. Analysts at Mizuho, H.C. Wainwright and LifeSci Capital downgraded the stock immediately afterward, citing the unexpected data and lack of disclosed details.&nbsp;<h2 class="st-heading-2">Stocktwits Users Cite David Lazar Upside For Kala Bio</h2>On Stocktwits, retail sentiment for Kala Bio was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:970/140;" src="https://news.stocktwits-cdn.com/kala_ss_png_9a4902a4d7.webp" alt="kala ss.png" width="970" height="140"><figcaption>KALA sentiment and message volume as of November 26 | Source: Stocktwits</figcaption></figure>One bullish user said, “<a href="https://stocktwits.com/symbol/KALA">$KALA</a> 1.50 next leg. David Lazar play. new<a href="https://stocktwits.com/symbol/CETY"> $CETY</a>.”<stembedurl>https://stocktwits.com/CAPITALWHISPERER/message/637454686</stembedurl>Another user said, “Look what david Lazzar did to $opgen and find out why he make<a href="https://stocktwits.com/symbol/KALA"> $KALA</a> investors very rich if they are patient.”<stembedurl>https://stocktwits.com/Frederickquan/message/637468005</stembedurl><a href="https://stocktwits.com/symbol/KALA">Kala Bio’s stock</a> has declined 91% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio’s stock (KALA) has declined 91% so far in 2025. (Photo credit: Getty Images)

Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse

A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default.

Equity

KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

KALA BIO (KALA) announced on Monday that its KPI-012 failed in a mid-stage clinical trial evaluating it as a treatment for persistent corneal epithelial defect.A persistent corneal epithelial defect (PCED) is a corneal injury that fails to heal within the typical timeframe of two weeks, persisting for weeks or even months despite standard treatment. Kala’s study to evaluate the safety and efficacy of two doses of KPI-012 ophthalmic solution did not meet the primary goal of complete healing of PCED at week 8, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.kalarx.com/news-releases/news-release-details/kala-bio-announces-topline-results-chase-phase-2b-clinical-trial">said</a>. It also noted that the secondary goals in the study did not achieve statistical significance, and there was no meaningful difference between the KPI-012 treatment arm and the placebo arm in the trial.The company subsequently decided to cease clinical development of KPI-012 and stated that it is evaluating its strategic options. The firm noted that it intends to preserve cash, including by laying off some of its workforce and implementing other cost-saving measures.Kim Brazzell, Chief Medical Officer of Kala Bio, said that the company is “disappointed” to see the new study results.“KPI-012 continued to be well-tolerated and demonstrated a favorable safety profile but did not demonstrate the efficacy results that would warrant advancing the program for treatment of front-of-the-eye diseases,” he added.Shares of the company slipped 89% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/KALA">KALA stock</a> rose to ‘extremely bullish’ from ‘neutral’ territory over the past 24 hours, while message volume rose to ‘extremely high’ from ‘high’ levels.Following the company’s announcement, LifeSci Capital downgraded Kala Pharmaceuticals to ‘Market Perform’ from ‘Outperform’ and removed the firm's price target on the stock.Mizuho analyst Graig Suvannavejh, meanwhile, expressed disappointment that the company did not share any data details or host a call to discuss the study results, as per TheFly. &nbsp;KALA stock is down by 69% this year and by about 62% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dogwood-therapeutics-stock-soars-pre-market-on-securing-license-for-cancer-related-pain-management-drug/chDubC3R3J2">Dogwood Therapeutics Stock Soars Pre-Market On Securing License For Cancer-Related Pain Management Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Kala Bio Stock Just Plunged 89% Today – Here’s What Happened

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures. 

Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks.com featured highlights include KALA, Graham, Arq and Hawkins

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Shares of Kala Bio Inc. tumbled over 35% on Wednesday, on track for their worst single-day decline ever, after the company announced the resignation of CEO Mark Iwicki.President Todd Bazemore has been named interim CEO, while Iwicki will remain as chair of the board.&nbsp;Iwicki, who has led Kala for nearly a decade, oversaw multiple phases of drug development.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/KALA_sentiment_and_message_volume_on_Feb_12_cdc55fd016.png" alt="KALA sentiment and message volume on Feb 12.png" width="1318" height="324"><figcaption>KALA sentiment and message volume on Feb 12 as of 2 pm ET | source: Stocktwits</figcaption></figure>Despite the steep selloff, retail traders on Stocktwits believe the market reaction is excessive, as evidenced by the 'extremely bullish' sentiment score.&nbsp;One user argued that Iwicki's departure "is the best thing possible for this company" and could signal a potential sale of the company after Kala's upcoming pipeline update.<stembedurl>https://stocktwits.com/Stmkr/message/603965500</stembedurl><stembedurl>https://stocktwits.com/Sammysums/message/603977842</stembedurl>Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects, a condition that can lead to vision loss.&nbsp;The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases, while its MSC-S platform is in preclinical studies for retinal degenerative conditions like Retinitis Pigmentosa and Stargardt Disease.At the end of 2024, Kala raised approximately $10.8 million through a private placement of common shares and Series I convertible preferred stock with institutional investors.The company is expected to report fourth-quarter earnings in March. Wall Street projects an adjusted loss per share of $2.28, down from $3.62 a year ago, on no revenue.Kala shares are down just 2.2% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Kala Bio Inc.

Yes — Rates Move Meaningfully Lower

Short-Term Dip, No Lasting Impact

No — Mostly Political Noise

Other – Comment Below

President Trump says he’s directing $200 billion into mortgage bond purchases to bring down rates and improve housing affordability. With questions around execution, authority, and real market impact, do you think this move will actually lower mortgage rates in 2026?

Will Trump’s Mortgage Bond Plan Actually Lower Rates in 2026?

KALA
KALA BIO Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KALA News

KALAKALA BIO Inc